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Introduction: Bariatric surgery (primarily Laparoscopic Sleeve Gastrectomy [LSG] and Roux-
en-Y Gastric Bypass [RYGB]) is an efficacious and durable therapeutic option for weight loss 
in obesity. The mechanisms that mediate weight loss following bariatric surgery remain 
incompletely understood.  
Areas Covered: Pubmed search of published data on faecal microbiota, metabolic health, 
LSG and RYGB. The faecal microbiome plays a key role in the establishment and 
maintenance of metabolic wellbeing, and may also contribute (through faecal dysbiosis) to 
metabolic dysfunction. LSG and RYGB both result in characteristic, procedure-specific 
changes to the faecal microbiota that may mediate at least some of the resultant weight-
loss and metabolically beneficial effects, when applied to the management of obesity. 
Expert Opinion: The human faecal microbiome, containing around 100 trillion microbes, 
evolved over millions of years and interacts symbiotically with its human host. Rodent-based 
studies have provided insights into the complexities of the gut-microbiome-brain axis. This 
includes the important role of the gut microbiome in the mediation of normal immunological 
development, inflammatory pathways, metabolic functioning, hypothalamic appetite 
regulation and the absorption of essential nutrients as by-products of bacterial metabolism. 
Faecal transformation is likely to provide an important therapeutic target for future 
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 The human gut microbiome co-evolved with our hominid ancestors over millions of 
years. Formed of approximately 100 trillion microbes, the gut microbiome vastly 
outnumbers our own cells. Over recent years, our understanding of the importance 
of the gut microbiome for health and wellbeing has been transformed. 
 Most of the current literature on the effects of gut microbiota (including faecal 
transplantation) on metabolic health stems from rodent studies. Data from human-
based studies on gut microbiota and metabolic health are largely association-based, 
enabling only tenuous conclusions regarding causality.  
 Most of our current data on the gut microbiome relates to individual bacterial 
species. Certain gut bacterial species such as Enterococcus, Akkermansia 
muciniphila and F. prausnitzii have been shown to associate with a favourable 
metabolic and inflammatory profile. Certain bacterial species release useful by-
products of metabolism. For example, Enterococcus, which through fermentation of 
dietary fibre, releases short-chain fatty acids (SCFAs) that confer metabolic benefits. 
(SCFA also contribute to around 10% of energy intake in humans, and therefore may 
potentially contribute to weight gain. The role of SCFAs in the establishment and 
maintenance of metabolic homeostasis therefore remains controversial [1, 2]).  
 Some gut bacterial species, such as Bacteroidetes and Firmicutes associate with 
human obesity. 
 Bariatric surgery is our most effective treatment strategy for obesity. The 
mechanisms of weight loss following bariatric surgery are incompletely understood, 
although current dogma implicates earlier release of incretins from the distal gut. 
 Based on the current literature (primarily studies on RYGB), characteristic 
modifications to the gut microbiome occur following bariatric surgery, and appear 
to be procedure-specific and largely metabolically-favourable (based on known 
associations of specific gut bacterial species). 
 Future studies should focus on attempts to replicate the characteristic modifications 
to the gut microbiome that normally occur following bariatric surgery. Such studies 
on patients with obesity would require transformation of the gut microbiome 
through, for example, faecal transplantation. Confirmation of established metabolic 
and appetitive benefits (including weight loss) from such an intervention, would 
provide a novel and promising therapeutic strategy, that could be implemented 
potentially on a global level for the prevention and management of obesity and 




The incidence of obesity has tripled since 1975, and affects more than 650 million people 
globally, with 1.9 billion people being overweight [3]. Obesity is associated with several 
non-communicable chronic diseases. These include metabolic dysfunction (such as Type 2 
Diabetes Mellitus [T2D], Hypertension, Dyslipidaemia, non-alcoholic fatty liver disease 
[NAFLD], and Obstructive Sleep Apnoea), biomechanical disorders (including osteoarthritis), 
cardiovascular, respiratory and psychiatric conditions, as well as increased risk of certain 
malignancies [4]. Obesity-related co-morbidities are likely mediated through complex 
pathways that implicate insulin resistance, hyperinsulinaemia, oxidative stress and 
inflammatory processes [5]. For example, ‘The Million Women Study’ showed a direct 
association of adiposity, as measured by Body Mass Index (BMI), with increased risk of cancer 
development (including 10 of 17 specific types of cancers) [6]. Furthermore, the 
Framingham Heart Study revealed obesity and overweight in adulthood to associate with 
decreased life expectancy and increased risk of early mortality, reduced life expectancy 
being similar to that of smoking [7]. The current global obesity epidemic, combined with 
the tsunami of obesity-related medical co-morbidities and chronic diseases, is one of the 
most important threats to our health in modern times. The global health-economic 
implications of obesity are substantial, and therefore the development and implementation 
of effective preventive and management strategies for obesity are a priority. This should 
incorporate a variety of approaches including multi-disciplinary team-based care, but also 
strategies that benefit the wider population. Development of novel therapeutic strategies 
for obesity will require renewed insight into the complex mechanisms that underlie both 
weight-gain, and effective weight-loss.  
 
Bariatric surgery represents our best current therapeutic option for establishment and 
maintenance of effective weight loss in obesity. However, despite its clear clinical and 
metabolic utility, the mechanisms by which bariatric surgery confer weight-loss benefits are 
incompletely understood. The ‘hind-gut hypothesis’ states that following gastric bypass 
procedures, there is earlier and enhanced release of incretin hormones from the distal 
ileum, stimulated by faster transit of food. This early incretin release suppresses appetite 
and augments post-prandial pancreatic response [8, 9]. However, this hypothesis remains 
speculative. It is important to explore alternate explanations for improvements in body 
weight and metabolic health following bariatric surgery. Renewed mechanistic insights 
would potentially enable catalysis of novel therapeutic developments, including non-
surgical replication of the weight-loss effects of bariatric surgery.  
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In recent years, the gut microbiome has assumed major interest within the scientific 
community. Current biomedical literature provides compelling support for the importance 
of a healthy colonic microbiome in the establishment and maintenance of health and 
wellbeing, and on gut microbial dysbiosis as an originator of much ill-health. This includes 
links to multiple chronic diseases, including T2D, autism, depression, auto-immunity, atopy, 
food intolerances and obesity. Indeed Hippocrates, the father of modern medicine, 
suggested that the root of all disease lies within the gut. There are increasing data in the 
literature, particularly from rodent and other animal models, that associate certain species 
of gut microbiota with body weight, metabolic profile and modulation of the immune system 
[10-15]. This raises a possible future role for faecal modulation (through, for example, 
faecal transplantation), for facilitating weight loss and improved metabolic profile. 
Currently, implementation of faecal transplants within the NHS is solely reserved for the 
management of patients suffering from intractable colonic colonisation with Clostridium 
difficile [16]. Future clinical indications for faecal transplantation are likely to diversify, 
given the emergent data that links the colonic microbiome with a spectrum that 
encompasses health and wellbeing, and chronic ill-health at opposite ends.  
 
In this concise review, we provide an overview of the gut microbiome and consider its 
relevance for maintenance of health and wellbeing, and as an originator of chronic ill-
health, including obesity. We then consider a possible role for changes in the gut microbiome 
as a mediator of weight loss, and other metabolically beneficial effects following bariatric 
surgery. We review critically the available evidence from the literature, using a Pubmed 
search of published data on faecal microbiota, metabolic health, LSG and RYGB, and provide 
suggestions for future directions in this important and emerging field.  
 
2. The Gut Microbiome 
2.1 The microbiome as we know it: There are approximately 100 trillion microbes within 
the human gut [17]. This number is well beyond our comprehension, although another 
perspective is that we are numerically more microbe than human (probably by an order of 
magnitude), if only taking into account numbers of cells. Whilst this may seem alarming or 
even disgusting to some, it is worth considering the essential role that the gut microbiome 
plays in the establishment and maintenance of health and wellbeing. Our gut microbiota co-
evolved with us and our ancestors over hundreds of millions of years. Accordingly, our 
immune system is intricately interlinked with our gut microbiome. The gut is the ultimate 
‘training ground’ for our immune system that empowers our immune defence following its 
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effective graduation. Without proper training from a rich and diverse gut flora, the immune 
system remains under-developed. In such a scenario, auto-immunity and atopy can ensue. 
Our gut microflora should be considered almost like an organ in its own right, with the 
capacity to make us unwell if not properly nurtured, or conversely to promote health and 
wellbeing if we nurture it correctly. Only around 1,000  microorganisms have been identified 
in the human body to date, of which 70% reside in the colon [18]. This probably represents 
a very small proportion of the total microbes within the gut. ‘Microbiome’ is an umbrella 
term that incorporates all non-Eukaryotic cells that associate with the human body, 
including locations such as skin, respiratory epithelia, genitourinary tract, and of course the 
entire gastrointestinal tract. However, the vast majority of microbes reside within the 
colon, which forms the main focus for this review.    
 
It is important that future studies focus on a more in-depth and complete understanding of 
the gut microbiome, not just through the identification of novel gut microbes, but also key 
insights into the mechanisms by which these microbes affect us. One of the challenges of 
this complex field relates to not just how individual microbes interact with their host, but 
also to how groups of different microbes interact with each other. It is possible, indeed 
likely that the beneficial or deleterious effects of a particular gut microbe is influenced by 
its immediate microbial environment.   
 
2.2 We are what our gut microbes eat: Our diet influences our gut microbiome. Typical 
modern-day western diets that are highly processed, sterile and often fat- and 
carbohydrate-rich, ultimately impoverish our gut microbiome. Conversely, natural, 
unprocessed and fibre-rich foods (including leafy green vegetables), encourage, nurture and 
facilitate development of a healthy and diverse gut microbiome. Although we are perhaps 
more what our gut microbiota eat than what we ourselves eat, we may never fully 
understand the mechanisms by which our gut microbiome influences our position on the 
health-disease spectrum. This field is inherently complex, and our understanding of how the 
gut microbiome mediates health and chronic disease remains in its infancy.  
 
2.3 The microbiome and macronutrients: An important function of the human gut pertains 
to nutrient and energy harvesting from macronutrients, including non-digestible 
macronutrients such as cellulose, through the action of intestinal enzymes from the host. 
For example, vitamins including biotin, folic acid, and pantothenate are synthesized by 
several intestinal genera, including Bacteroides, Eubacterium, Propionibacterium, and 
Fusobacterium [19]. Conversely, some gut microbes (eg. B. thetaiotaomicron) can actually 
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compete with the host for essential nutrients, such as B12. Indeed, Wexler and colleagues, 
using Western blot analysis from custom-made rabbit anti-BtuG2 polyclonal antibody, 
showed that some gut microbes such as B. thetaiotaomicron, actually utilize vitamin B12 on 
transit through the digestive tract. BtuG (a surface-exposed lipoprotein essential for B12 
transport in B. thetaiotaomicron), binds with great affinity to B12, and even sequesters B12 
from intrinsic factor in humans [20]. Accordingly, BtuG reduces the host’s own absorption 
of B12. This highlights how some gut microbes appear to play a duplicitous role with regards 
to certain macronutrients, including both provision of essential nutrients such as biotin and 
folic acid, and competition with the host for other essential nutrients such as B12. 
 
2.4 Identification of the gut microbiome: Accurate analysis of gut microbiota composition 
is important to enable insights into associations between gut microbiota signatures and 
disease. There are two main approaches: i) Shotgun next generation sequencing 
metagenomics analysis of random DNA fragments, and; ii) 16S ribosomal RNA gene (rDNA) 
amplicon sequencing [21-24]. Laudadio and colleagues reported on one of the few studies 
to directly compare application of these two approaches on the same faecal samples. It was 
demonstrated that compared with 16S rDNA amplicon sequencing, the Shotgun 
metagenomics approach provided a much deeper characterization of the microbiome 
complexity, with identification of a larger number of species [24]. A further means of 
assessing the human gut microbiome is through ‘quantitative microbiome profiling’ that 
enables measurement of overall absolute microbial abundance, (rather than relative 
abundance that is simply reported as fractions within each faecal sample) [25]. Data from 
quantitative microbiome profiling provides insights into how quantitative changes in 
microbial species may influence metabolite concentrations and physiological parameters 
[25]. 
 
Comparison of the microbiome across two or more subjects has proved challenging. 
Accordingly, the microbial signature is broken down into two main categories: the number 
of different species in a faecal sample, and the abundance with which each species appears. 
Within a faecal sample from a single human, microbial signature is referred to as ‘α-
diversity’. When faecal samples from two different human sources are compared, the 
difference between the two samples is referred to as ‘β-diversity’ [26]. Data from such 
studies reveal that most human gut microbiota are members of the Firmicutes and 
Bacteroidetes phyla [27-30]. Overall, there are six main bacterial clusters that inhabit the 
gut of healthy individuals. These include Firmicutes (gram-positive strains of Clostridium, 
Eubacterium, Ruminococcus, Butyrivibrio, Anaerostipes, Roseburia and Faecalibacterium); 
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Bacteroidetes (gram-negative strains of Bacteroides, Porphyromonas and Prevotella); 
Proteobacteria (gram-negative strains such as Enterobacteriaceae); Actinobacteria (gram-
positive Bifidobacterium genus); Fusobacteria, and; Verrucomicrobia (Akkermansia) [31, 
32].  
 
3. Clinical Relevance of the Human Gut Microbiome for Obesity and Metabolic 
Status 
Most of the existing data on the gut microbiome and its association with body weight and 
metabolic health stems from rodent-based studies. There are relatively few human-based 
studies reported. Thus, it is important that we conduct future well-designed studies in 
humans to corroborate the rodent-based data, to develop novel insights into a potential 
future therapeutic role for gut microbiota as an important mediator of a healthy metabolism 
and body weight. Most of the human-based literature to date report on association between 
BMI and groups of bacterial species. We know relatively little about the metabolic effects 
of, and interactions between individual bacterial species within the human gut. 
 
3.1 Association of the gut microbiome with obesity: Human obesity associates with two 
main bacterial species predominant within the gut:  Bacteroidetes and Firmicutes [33, 34]. 
In one study reported by Ley and colleagues, genetically obese mice (ob/ob) were compared 
with lean (ob/+) and wild-type siblings, that were fed on the same diet and had their gut 
microbiomes sequenced via 16S rRNA gene sequences. As expected, Firmicutes and 
Bacteroides predominated within the gut microbiome of the obese (ob/ob) mice. There was 
also a 50% reduction of Bacteroides and proportional increase of Firmicutes in the ob/ob 
mice compared to the ob/+ mice. [35]. Human-based studies show that obesity associates 
with other gut microbiota that include the genera Alistipes, Anaerococcus, Corpococcus, 
Fusobacterium and Parvimonas [36]. 
 
3.2 The gut-microbiome-brain axis: Much of our insights into the complexities of the gut-
microbiome-brain axis originate from metabolomics data. Such studies target small 
molecule metabolites through a variety of mass spectrometry-based techniques, including 
gas chromatography, liquid chromatography and capillary electrophoresis [37]. 
Metabolomics data from rodent-based studies underlies much of our current understanding 
of the gut-microbiome-brain axis, with implication of neuro-immune, neuroendocrine and 
autonomic (primarily vagal) pathways [38]. The actual mechanisms involved are 
incompletely understood. It is possible that direct communication between the gut 
microbiome and brain occur, through the release of chemicals [38, 39]. Direct microbiome-
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brain communication may be mediated through release of by-products from gut microbes 
such as SCFAs, secondary bile acids and tryptophan metabolites [38, 40]. These molecules 
may initiate signals via enteroendocrine cells, enterochromaffin cells and the mucosal 
immune system. Some microbial by-products (such as SCFAs) cross the intestinal barrier to 
enter the systemic circulation, and some may also cross the blood-brain barrier to exert 
direct effects on hypothalamic regulation of appetite and metabolic processes [41, 42]. 
Secondary bile acids are products of the gut microbiota following their metabolism of bile 
acids (synthesized from cholesterol within the liver). These gut microbiota-induced 
bioconversions are known to modulate the signalling properties of bile acids through the 
nuclear farnesoid X receptor and the G protein-coupled membrane receptor 5 [43]. These 
pathways regulate multiple metabolic pathways in the host. Furthermore, the gut 
microbiota composition can itself be regulated through the action of bile acids (including 
through modulation of the intestinal innate immune response) [43]. Therefore, secondary 
bile acids play an important role in the maintenance of a healthy gut microbiota, insulin 
sensitivity, innate immunity and balanced lipid and carbohydrate metabolism [44, 45]. In 
addition to metabolic dysfunction, aberrant bioconversion of bile acids into secondary bile 
acids resulting from faecal dysbiosis, has also been linked mechanistically with 
gastrointestinal carcinogenesis (including colorectal cancer and hepatocellular carcinoma) 
[44]. 
 
Observations consistent with a role for gut wall ‘leakiness’ in metabolic health include those 
reported in a human-based study by Chassaing and colleagues [46]. In colonic biopsies, 
bacterial-epithelial distance (the distance between the gut microbiota and the gut epithelial 
lining and a marker of colonic mucus production), was shown to inversely correlate with 
BMI, fasting glucose levels and HbA1C. These data are consistent with a local effect of gut 
microbiota on colonic mucus production and permeability of the gut wall. Therefore, mucus-
mediated gut wall permeability may influence metabolic status through physical protection 
of the gut epithelial lining from gut microbiota [46]. Gut microbiota are likely to play an 
important role in the control of secretion and thickness of gut mucus and its subsequent 
metabolic implications, although this hypothesis requires confirmation.  
 
The realm of interconnections and communications within the gut-microbiome-brain axis 
should provide a focus for future research, to provide novel insights into the regulation of 
appetite, metabolism and even emotional regulation and mental health. Evidence from the 
literature provides useful insight into the potential effects of some species of human gut 
microbiota on body weight and metabolic status, mediated through the gut-microbiome-
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brain axis (outlined in Table 1). To further explore the intricacies of the gut-microbiome-
brain axis, we outline here some insights into potential roles of individual species of gut 
microbiota and some of their metabolic by-products. 
 
3.3 Akkermansia muciniphila: This is a mucin-degrading bacterium that may play a role in 
human gut barrier function, and thereby influence host metabolism through modulation of 
translocation of microbial molecules across the gut wall [47]. In one study reported by Clarke 
et al. on gut microbiota from professional rugby athletes compared with controls, it was 
shown that athletes and the low BMI controls had significantly higher proportions of the 
genus Akkermansia than the high BMI controls [48]. Through the reduction of intestinal 
mucin to propionic and acetic acid, Akkermansia muciniphila engages in symbiosis with its 
host, providing nutrients accessible for other resident gut bacteria [49, 50]. Interestingly, 
colonic Akkermansia muciniphila levels have also been shown to be decreased in adults with 
obesity and T2D [50]. 
 
3.4 Enterococcus: Gut microflora may influence appetite through direct or indirect 
communication with the hypothalamic appetite centres. One such colonic bacterial species 
is Enterococcus, a gram-positive facultative anaerobe of the genus lactobacillus, and phylum 
Firmicutes. Enterococcus ferments dietary fibre, producing SCFAs in the process. Levels of 
colonic Enterococcus and its by-product SCFAs directly correlate with appetite inhibition. 
Future studies should explore further the causal mechanisms (direct and/or indirect) 
between colonic Enterococcus and SCFAs and appetite regulation [23].  
 
3.5 Faecalibacterium prausnitzii: It has been demonstrated that some species of colonic 
bacteria, including the gram-positive anaerobic Faecalibacterium prausnitzii associate with 
anti-inflammatory effects post-bariatric surgery [51]. Mediation of anti-inflammatory 
effects of F. prausnitzii may occur through blockade of nuclear factor-kB activation, and 
subsequent inhibition of secretion of pro-inflammatory mediators [51-53]. Other studies 
have shown possible effects of Gram-positive anaerobic bacteria on the production of 
butyrate, a SCFA. An increased proportion of butyrate-producing bacteria within the gut 
microbiome associates with a favourable metabolic profile in humans [54]. The 
mechanism(s) by which butyrate confers metabolic benefit may include anti-inflammatory 
effects, and enhancement of intestinal barrier function.  
 
3.6 Short Chain Fatty Acids (SCFAs): The gut microbiome utilizes energy from food 
products, producing some by-products that are beneficial to the host. SCFAs are one such 
by-product of microbial respiration. SCFAs are produced by anaerobic microbes within the 
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caecum during fermentation of dietary fibre (non-digestible carbohydrates). SCFAs appear 
to provide a source of energy for colonocytes [55]. Furthermore, human-based studies have 
shown that SCFAs can pass through the colonic epithelium into the bloodstream. Serum 
SCFAs may then influence lipid, glucose and cholesterol metabolism through effects on G 
protein-coupled receptors (GPCRs) [55]. GPR41/FFAR3 (free fatty acid receptor 3) and 
GPR43/FFAR2 are two SCFA-specific GPCRs expressed in the gut entero-endocrine cells, 
adipocytes, and immune cells [56]. Compared with GPR41 knock-out mice, stimulation of 
GPR41 on entero-endocrine cells in wild-type mice with SCFAs demonstrated enhanced 
secretion of peptide YY (PYY), a gut hormone with appetite-suppressant effects. Other 
effects in the wild-type mice from GPR41 stimulation with SCFAs included increased gut 
motility, and reduced harvesting of energy via SCFAs from the diet [57]. SCFA-dependent 
effects of GPR43 signalling in wild-type mice demonstrated enhanced incretin (glucagon-
like peptide-1, GLP-1) release, and enhanced insulin sensitivity [58].  
 
The beneficial effects of SCFAs in rodent-based studies have been corroborated by 
observations from human-based studies. In one study by Chambers et al., the effects of 
propionate (one of the commonest SCFAs produced by human gut microbiota) on incretin 
response (including plasma PYY and GLP-1 excursions), body weight and energy intake were 
explored. A novel inulin-propionate ester was utilized in a randomised, controlled cross-
over design in overweight adults (n=60). Ingestion of propionate resulted in early 
postprandial release of PYY and GLP-1 from human colonic cells, with associated reduction 
of subsequent energy intake. Over 24 weeks of regular propionate ingestion (compared with 
an inulin control group), there was significant weight loss, reduction in intra-abdominal 
adipose tissue volume and intra-hepatocellular lipid content and preservation of insulin 
sensitivity [59]. These data provide compelling insight into possible mechanisms by which 
gut microbiota mediate metabolic health through the effects of SCFAs on incretin release, 
adipocyte and immune cell functioning. Dietary fibre, as a key source of colonic SCFAs, 
remains an important component of a healthy diet.   
 
3.7 Succinate: In addition to the association of colonic bacterial species and their by-
products (such as SCFAs) on favourable metabolic status, other bacterial species and by-
products associate with unfavourable metabolic status. Succinate is a metabolic 
intermediate by-product produced by some bacterial species. Serum succinate levels in 
humans, including a predominance of succinate-producing colonic bacterial species such as 
Prevotellaceae and Veillonellaceae, associate with obesity and metabolic syndrome. 
Furthermore, weight-loss has been observed to accompany a reduction in levels of serum 
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succinate, and increased proportion of succinate-consuming colonic bacteria that include 
Odoribacteraceae and Clostridiaceae [60]. It is not clear whether succinate plays a causal 
role in determining body weight and metabolic status, or the nature of such mechanisms. 
 
To summarize this section (outlined in figure 1), certain colonic bacterial species (including 
Akkermansia muciniphila, Enterococcus and F prausnitzii), and bacterial by-products such 
as SCFAs, appear to associate with a more favourable metabolic status, including lower 
appetite, lower body weight and reduced overall inflammatory status. Conversely, other 
bacterial species that include Prevotellaceae and by-products such as succinate, associate 
with an unfavourable metabolic status. It is important to re-emphasize that the studies 
outlined here on bacterial proportions are mainly based on association data. Causal effects 
of colonic microbiota and their by-products on regulation of appetite, metabolic and 
inflammatory milieu, and the mechanisms implicated (including ‘gut-microbiome-brain’ 
interlinked communications) are largely speculative. It remains possible that association of 
colonic microbiota species with favourable body weight and metabolic status, are merely 
epiphenomena that play no causal role in the establishment of metabolic and inflammatory 
status. However, evidence exists both from rodent- and human-based studies, to implicate 
colonic bacterial by-products such as SCFAs, in the mediation of at least some of the 
metabolic effects of the gut microbiome on human metabolic status.  
 
There is much interest in the interactions between the host mitochondria and microbiota. 
Complex bi-directional interlinks exist between these two entities, with the gut microbiota 
implicated in the regulation of key transcriptional co-activators, enzymes and transcription 
factors involved in mitochondrial biogenesis. SCFAs and secondary bile acids derived from 
the gut microbiota also influence host energy production and inflammation, with 
implications for athletic performance [61]. Furthermore, mitochondrial function (including 
mitochondrial production of reactive oxygen species) play an important role in the 
regulation of the gut microbiota, including the intestinal barrier function and mucosal 
immune responses. Such processes may be influenced through genetic variants within the 
mitochondrial genome  [61]. A link between colonic butyrate has been shown with autism 
spectrum disorder, with mitochondrial dysfunction as a possible mediator [62].   
 
3.8 Metabolic Effects of Faecal Transplantation: To move beyond mere association and 
address further the important question of causality will require novel investigation. This will 
include modification of the human gut microbiome through means such as faecal 
transplantation, and to explore the related metabolic and inflammatory effects. This will 
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be an important step towards a future that places gut microbiota at centre stage, and one 
that seeks to improve health and wellbeing of the populace through re-establishment of a 
healthy and well-nurtured gut microbiome. Important insights into possible metabolic 
effects of faecal transplantation stem from rodent-based studies. Most reported data to link 
gut microbiota with obesity stem from murine models, with demonstration of changes in 
both metabolic status and body weight following faecal transplantation [63]. One important 
caveat when comparing faecal microbiota between humans and rodents, is that rodents 
recover some energy requirements from coprophagia that is likely to influence their colonic 
microbiota in ways that do not apply to humans [64, 65]. Caution should therefore be 
exercised when extrapolating rodent-based data on faecal transplantation to humans. 
Although two human studies on faecal transplantation have shown improvements in glucose 
tolerance in metabolic syndrome, to date there are no current human-based data that 
demonstrate effectiveness of faecal transplantation in treating obesity [63, 66]. 
 
Studies using faecal transplantation in germ-free (gnotobiotic) mice have identified 
Prevotella copri as an important contributor to branched-chain amino acids and insulin 
resistance. However, in other faecal transplantation studies, P. copri was demonstrated to 
be required for improved insulin sensitivity [1, 67]. In a further study on gnotobiotic mice, 
colonization with a prominent saccharolytic member of the normal human gut microbiota 
resulted in a marked improvement in the efficacy of colonic fermentation, increased de 
novo lipogenesis and obesity [64, 68]. Rodent-based studies have also provided insights into 
interplay between the gut microbiota and the reproduction axis in a rat model of Polycystic 
Ovary Syndrome (PCOS). Guo and colleagues randomly assigned rats into control and PCOS 
groups (induced through letrozole treatment, with elevated levels of testosterone and 
suppressed oestradiol) [69]. One PCOS rat group received colonic Lactobacillus that 
associated with increased levels of oestradiol. A separate PCOS rat group received faecal 
microbiota transplantation that associated with a reduction in faecal Prevotella, and 
reduced levels of serum testosterone and androstenedione [69]. Interestingly, there were 
also effects of letrozole treatment (and inducement of PCOS) on faecal microbiota, with 
lower levels of Lactobacillus, Ruminococcus and Clostridium and higher levels of Prevotella 
(compared with the control group) [69]. 
 
Having explored associations of the human gut microbiome with metabolic health and body 
weight, and the symbiotic relationship of colonic microbiota with the host, we now consider 
evidence to support modification of the gut microbiome as a mediator of weight loss and 
metabolic improvement following bariatric surgery.  
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4. Bariatric Surgery and the Gut Microbiome  
4.1 Bariatric Surgical Procedures: Currently, there are three main types of bariatric 
surgery: Laparoscopic Gastric Band (LGB), Roux-en-Y Gastric Bypass (RYGB) and 
Laparoscopic Sleeve Gastrectomy (LSG). There is incomplete understanding of the 
mechanisms of weight-loss and metabolic improvement following each of these procedures, 
including the degree of mechanistic overlap between them. In recent years, a trend has 
emerged for LSG, although RYGB also remains a popular choice [70] and both RYGB and LSG 
have been shown to confer beneficial effects on weight loss and resolution of T2D [71]. For 
the purposes of this review, we will not consider procedures such as gastric balloon 
insertion, and only focus on the two most frequently-performed bariatric surgical 
procedures, RYGB and LSG.   
 
The magnitude of weight loss following bariatric surgery varies according to the type of 
procedure. Typically, greatest weight loss occurs following RYGB. In one study, percentage 
of excess weight loss (%EWL) following RYGB was 62.58% at ≥5 years and 63.52% at ≥10 years. 
Comparative values following LGB were 47.94% and 47.43% respectively. Following LSG, 
there was 53.25 %EWL at ≥5 years [72]. However, more recent comparisons between weight-
loss effects of RYGB and LSG at 5-years post-procedure have shown equivalent effects. Data 
from the Swiss Multicenter Bypass or Sleeve Study (SM-BOSS) that reported on 217 morbidly 
obese patients randomly assigned to either RYGB or LSG, showed statistically equivalent 
weight-loss at 5-years following the procedure (excess BMI loss of 68.3% and 61.1% 
respectively) [73]. A further independent ‘sleeve vs bypass’ (SLEEVEPASS) study on 240 
morbidly obese patients randomly assigned to RYGB or LSG, also showed statistically 
equivalent weight-loss (based on pre-specified equivalence margins) at 5-years post-
procedure (estimated mean %EWL of 57% and 49% respectively) [74]. 
 
Effects of bariatric surgical procedures on both GI anatomy and physiology influence the 
speed of food transit from the stomach into the ileum. Both RYGB and LSG diminish the 
effects of gastric acid on ingested food within the alimentary tract. Furthermore, bariatric 
surgery often results in changes in dietary habits and eating behaviours. Following bariatric 
surgery, changes in gastro-intestinal (GI) anatomy and physiology that influence the speed 
of food transit through the upper alimentary tract and exposure of salivary microbiota to 
gastric acid, and changes in diet and eating behaviour may all have down-stream effects on 





4.2 The effects of bariatric surgery on the gut microbiome: The type of bariatric 
procedure appears to influence the form of modification to the colonic microbiome. 
Compared with RYGB, LSG does not change the anatomical arrangement of the gut, and 
therefore results in less dramatic changes in the rapidity and diversity of the adapting gut 
microbiome. In support of this hypothesis, Sanmiguel et al. reported on a study of obese 
women (n=8) who had undergone LSG. At one month post-LSG, there were no substantive 
changes in gut microbial diversity compared with pre-LSG [23]. However, LSG does appear 
to result in colonic microbial changes in some studies, including one in young (age 18-30 
years) Chinese obese subjects (n=23), in which the relative abundance of colonic 
Bacteroides thetaiotaomicron increased with weight-loss post-LSG, and continued to 
increase with further weight-loss [75]. 
 
In RYGB, a small gastric pouch is formed with bypassing of the distal stomach and proximal 
small intestine, through the attachment of the distal end of the jejunum to the proximal 
gastric pouch. The ‘bile and pancreatic limb’ is attached along the Roux limb. RYGB results 
in reduced acidity along the length of the gut, and downstream delivery of bile acids. 
Changes in gut pH and bile acid exposure following RYGB both likely influence the 
composition of the gut microbiome [23, 51, 76]. Lee and colleagues performed 16S rRNA 
amplicon sequencing in women with Diabetes Mellitus (mean age 51 years and 75% black 
race), to identify gut microbial composition at baseline, and following 10% weight loss (or 
at 9-months post-bariatric surgery if 10% weight loss was not achieved). Women were 
randomised to medical weight loss (MWL), LGB or RYGB in a ratio of 1:1:1, each group 
containing the same number (n=4) of participants. The MWL group received individualized 
counselling, combined with meal replacements and frequent self-monitoring. Daily caloric 
consumption was 1200–1500 Kcal for adults weighing <220 lb, and 1500–1800 Kcal for adults 
weighing >220 lb. Mean weight loss across each of the 3 groups, MWL, LGB and RYGB was 
6.3%, 9.9% and 10% respectively. Although relatively little gut microbial diversity was 
observed at baseline amongst this small sample size, both RYGB and LGB resulted in an 
increased proportion of Proteobacteria within the gut microflora [22], and RYGB also 
resulted in an increased proportion of Actinobacteria [22]. The MWL group showed minimal 
change in the relative abundance and types of gut microbiota following weight loss, but 
showed an increase in the relative abundance of Roseburia genus compared to RYGB and 
LGB. There were no changes in the proportion of Bacteroides species within the gut 
microbiome amongst those who had undergone bariatric surgery regardless of type, but an 
increase in the relative abundance of Faecalibacterium in those who had RYGB compared 
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to LGB and MWL. Also, there was a relative increase in the abundance of Akkermansia genus 
in all three MWL, LGB and RYGB groups [22].  
 
Sanchez-Alcoholado and colleagues reported on the effects of bariatric surgery (RYGB [n=14] 
and LSG [n=14]) on the colonic microbiome, through sequencing of amplicons from the 16S 
rDNA gene by next-generation sequencing. Spanish subjects with morbid obesity (n=28) were 
recruited, with assessments at baseline and at 3-months post-bariatric surgery. Following 
LSG, there was an increase in the relative abundance of Verrucomicrobiaceae species. 
Conversely following RYGB, there was an increase in the relative abundance of 
Enterobacteriaceae, Proteobacteria and Fusobacteria [34]. There was also an inverse 
correlation between Enterobacteriaceae and Veillonella and cholesterol levels, and a 
positive correlation between Verrucomicrobia members and high-density lipoprotein 
cholesterol both pre-and post-bariatric surgery [34]. Interestingly, those subjects who 
underwent RYGB also had an increase in the relative abundance of facultative anaerobes 
(that typically originate from the oral tract) in their gut microbiome. These included 
Fusobacteria, Veillonella, and Granucatiella [34]. 
 
One explanation for the increase in the relative abundance of colonic facultative anaerobes 
following RYGB includes faster transit of swallowed saliva through the stomach remnant into 
the ileum, and perhaps reduced exposure of salivary microbes to gastric acid following 
RYGB. Through this mechanism, it is conceivable that more oral anaerobes within saliva 
reach the ileum following RYGB and contribute towards modification of the gut microbiome. 
However, this hypothesis is entirely speculative, and should form a focus for future research. 
It is also possible that differences in gastric pH following LSG and RYGB (including increased 
gastric pH following RYGB compromising the gastric pH barrier [77], and resulting in a higher 
intestinal pH [78]), may influence directly the colonic microbiome, and may explain some 
of the differences in colonic microbial modification following each of these procedures. It 
remains possible that changes in salivary transit speed following RYGB may affect the 
microbiota throughout the entire GI tract, and not just the colon. These potential changes 
in GI microbiota following RYGB should form a focus for future research. 
 
Changes in the colonic microbiome following bariatric surgery also associate with changes 
in appetite and measures of food addiction. Using the Yale Food Addiction scale, Sanmiguel 
and colleagues showed increased levels of certain species of colonic bacteria that associate 
with a reduction in food addiction following LSG. These species included Butyricimonas, 
Odoribacter and Enterocococcus. Conversely, there were reduced levels of other species of 
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colonic bacteria, such as Catenibacterium and Anaerostipes [23]. It is possible that causal 
mechanisms implicating effects of these bacterial species on appetite and food addiction 
pertain, and should be a focus for future research. In a further study on the effects of LSG 
in women with obesity (n=8), levels of colonic Enterococcus associated inversely with 
perceptions of hunger post-LSG [23].  
 
To summarize this section, it appears that both RYBG and LSG result in modifications to the 
colonic microbiome. The nature, diversity and rapidity of such modifications appear to be 
procedure-specific. Although this review has focused primarily on the colon, it is worth 
noting that the gut microbiota extends throughout the entire gastro-intestinal tract, from 
mouth to anus. Most studies to date have focused on the colonic microbiota, partly due to 
its accessibility through faecal assessment. It remains possible, however, that important 
changes in the gut microbiota more proximally (such as within the small intestine) occur 
following bariatric surgery, and play an important role in the mediation of metabolic 
benefits. This is particularly relevant for RYGB, and the potential impact on the ileal 
microbiota of the anatomical location of the alimentary limb anastomosis (which in turn 
influences the degree of food mixing with biliary and pancreatic juices). This should form a 
focus for future research. 
 
Based on current evidence, generally the changes in the colonic microbiome following RYGB 
and LSG appear favourable. However, it is not clear whether such changes in the microbiome 
post-bariatric surgery simply reflect epiphenomena, or are implicated causally with 
hypothalamic control of appetite and metabolic processes. Further studies on the effects of 
bariatric surgery on the colonic microbiome in larger sample sizes are required, to validate 
the findings from the studies outlined here. To prove causality will require interventional 
studies (such as faecal transplantation) that manipulate the colonic microbiome in some 
way, with close observation of subsequent effects including appetite, metabolic processes 
and inflammatory and immune status. Insights gained from such interventional studies will 
act as a forerunner for future development of novel therapeutic approaches that manipulate 
the colonic microbiome, to replicate the favourable modifications that occur following 
bariatric surgery. 
 
5. Expert Opinion 
The human faecal microbiome, which contains approximately 100 trillion microbes, has co-
evolved with our hominid ancestors over millions of years and forms a hugely complex 
biological system. The colon plays an essential role in the establishment and maintenance 
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of health and wellbeing, coordinated by its resident myriad microbiota. This includes the 
mediation of normal immunological development, inflammatory pathways, metabolic 
functioning, links with hypothalamic appetite regulation and the absorption of essential 
nutrients as by-products of bacterial metabolism.  Such reliance on our prokaryotic cousins 
is not without precedent. During early eukaryotic cell development, it is thought that 
mitochondria originated from cellular phagocytosis of a separate prokaryotic cell. Our 
mitochondria probably originated from a bacterium, and form an essential component of 
our eukaryotic cells. Our gut microbiome is not part of us in the sense of being within our 
own cells, but nonetheless plays an essential role in our normal physiological functioning.  
 
Although our understanding of the important symbiotic roles played by the gut microbiome 
(including the mediation of normal physiological functioning) has been transformed over 
recent years, it remains in its infancy. The majority of our current understanding stems from 
rodent-based studies, including demonstration of metabolic changes following faecal 
transplantation. Data from human-based studies are mainly observational in nature. Such 
studies usually provide association data, but proof of causality often remains elusive. 
However, it is clear from human-based studies that certain types of microbiota associate 
with a healthy body weight and metabolic profile, whilst others associate with obesity and 
metabolic dysfunction. Furthermore, as outlined in this review, human faecal microbiota 
are modifiable. Following bariatric surgery (including LSG and RYGB), there are changes in 
microbiota signature that appear procedure-specific. There is compelling evidence for 
beneficial effects of certain microbiota species, such as those that produce SCFAs. However, 
for the majority of identified species of microbiota, it is unclear whether their association 
with metabolic homeostasis or dysfunction is causal or incidental, the latter possibly as a 
by-product of other causal mechanism(s).  
 
Rodent-based data provide evidence regarding possible causal roles of the gut microbiome 
on metabolic health, particularly studies that explore faecal transplantation between 
rodents, and resultant changes in body weight and metabolic processes. Bariatric surgery 
remains our most effective treatment strategy for facilitation of weight loss in patients with 
obesity. However, bariatric surgery cannot be implemented on a population-based level. 
Furthermore, despite being an established therapeutic option implemented globally for 
decades, we do not fully understand the precise mechanisms that mediate the weight loss 
and metabolic benefits of bariatric surgery. The current hind-gut hypothesis, based on 
enhanced release of incretin hormones from the distal ileum following a meal, seems 
incomplete and is probably an over-simplification. Data outlined in this review provide 
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evidence for characteristic modifications to the gut microbiome following bariatric surgery 
that appear to be procedure-specific. Furthermore, changes in the gut microbiome post-
bariatric surgery appear mostly favourable, based on known associations of specific gut 
bacterial species with metabolic status. It is possible that changes in gastric pH following 
RYGB and LSG, and the faster transit of salivary bacteria into the ileum, may explain at 
least partly, the presence of facultative anaerobes in the gut microbiome following these 
procedures shown in some studies. It is also possible that changes in macronutrient 
ingestion, and eating-related behaviour (such as slower eating) following bariatric surgery 
may also contribute towards some of the changes in the gut microbiome. 
  
Ultimately, weight loss and metabolic benefits of bariatric surgery are likely to result from 
complex mechanisms involving numerous systems. It would perhaps be an over-
simplification to consider that such benefits ensue from just one overriding mechanism such 
as early incretin release, or even modification of the gut microbiome. However, in the 
context of bariatric surgery, alteration, adaption and transformation of the gut microbiome 
has received less attention so far. Studying the gut microbial signature prior to and following 
bariatric surgery may better inform clinical practice, since the gut microbiome appears to 
play a central role in wellbeing, and manifests intriguing connections with the brain, 
including hypothalamic regulation of appetite and metabolic processes. We therefore need 
to further explore the notion that modification(s) of the gut microbiome following bariatric 
surgery may mediate important metabolic benefits. An important future step will be to 
replicate such changes in the gut microbiome that occur following bariatric surgery, through 
faecal transplantation or other means in patients with obesity, and provide evidence to 
confirm or refute this novel and intriguing hypothesis. If confirmed, modulation and 
transformation of the gut microbiome would offer a novel and promising therapeutic 
strategy potentially on a global scale, in the effective prevention and management of 
obesity and metabolic dysfunction.  
 
It is our view that the human faecal microbiome deserves the focus of future research, since 
almost the entire spectrum of modern-day chronic cardio-metabolic, and non-
communicable ill-health is likely linked to faecal dysbiosis. Our modern, highly-processed, 
sterilized and fibre-impoverished diets are probably largely to blame. Such diets are the 
antithesis to what our hominid ancestors would have eaten, and what our species evolved 
to eat. Perhaps in our drive to avoid gastroenteritis and satisfy our pleasure centres that 
respond to the hedonic effects of food, particularly the sugar-fat combination frequently 
contained in our modern diet, we have deviated far from what constitutes a normal/healthy 
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diet [79]. A healthy faecal microbiome thrives on plant-based fibre, (which most of us simply 
don’t eat enough of), and requires careful nurture. A useful analogy here is providing 
fertilizer for effective growth of plants in a garden. Fertilizer for our gut microbiome is non-
digestible fibre from natural plant foods, but also non-sterilized foods (kefir and sauerkraut 
being examples). We should view our gut microbiome as a guardian of our health and 
wellbeing. A guardian that requires constant nurture. Without requisite nurture, our gut 
microbiome can become an adversary to our health, and instead promote chronic ill health. 
As we have no option to walk away from our gut microbiome, our health and wellbeing 
remains utterly dependent upon it. We need to nurture our gut microbiome throughout life, 
to maintain our friendship with it, so that it can protect our health and wellbeing as we age.  
 
To move beyond data that merely confirm association, there is a strong imperative for the 
generation of a firm evidence-base from focused research in this field. This should include 
active transformation of faecal microbiota from dietary change or faecal transplantation, 
or some other novel future means of modifying the faecal microbiota (such as, for example, 
a faecal capsule). It remains unclear whether the weight-loss and metabolic benefits of 
bariatric surgery are conferred through associated changes in the faecal microbiota. To 
address this question directly will require replication of the characteristic changes in the 
faecal microbiome that occur following bariatric surgery, followed by careful observation 
of subsequent changes in body weight and metabolic profile. In this way, it may be possible 
to re-create some of the beneficial metabolic effects of bariatric surgery, without the need 
for surgery itself. Bariatric surgery remains our most efficacious and durable therapeutic 
option for effective obesity management. However, bariatric surgery is a limited resource 
that cannot be scalable as a viable therapeutic option on a population level. Through 
bypassing the need for surgery, faecal transformation, if shown to confer beneficial weight 
loss and metabolic effects, could potentially be implemented as an effective weight 
management strategy, scalable to the population level.  
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 Modulates translocation of microbial molecules across gut wall [49] 
 Engages in symbiosis with host 
 Provision of nutrients accessible for other gut bacteria [51, 53] 
 Levels decreased in adults with obesity and Type 2 Diabetes [53] 
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 Associated with anti-inflammatory effects post-bariatric surgery [54] 
 Blockade of nuclear factor-kB activation 
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